12,372 trials
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 4.1; 4.2; 1.8; 2.9…
Pain, Postoperative
Primary: Wake Time After Sleep Onset (WASO) Measured by Actigraphy — 143.7; 230.9; 214.0; 431.4 Minutes — p=0.0002
Diabetes Mellitus, Type 2 · Hypertension
Primary: HbA1c Change From Baseline — 0.03; -0.59; -0.63 percentage of HbA1c — p=<0.0001
Diabetes Mellitus, Type 2 · Obesity
Primary: Change From Baseline in HbA1c After 18 Weeks of Treatment — -0.50; -0.94; -1.02 percentage of HbA1c — p=<0.0001
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline — -0.11; -0.59; -0.72 percentage of HbA1c — p=<0.0001
Healthy
Primary: Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA)…
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline — -0.13; -0.70; -0.77; -2.78 percentage of HbA1c — p=<0.0001
Diabetes Mellitus, Type 2 · Renal Insufficiency
Primary: HbA1c Change From Baseline in Patients With Mild or Moderate Renal Impairment — 0.05; -0.46 percentage of HbA1c — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks — 0.06; -0.66; -0.77; -0.65 percent of HbA1c — p=<0.0001
Smoking
Primary: Rate of Successful Smoking Cessation at Week 6 — 24.48; 21.49; 30.83; 20.17 Percentage of participants — p=0.3851
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks — -0.013; 0.116; 0.140; 0.137 Liter — p=<0.0001
Pain
Primary: Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product — 39.6; 45.0 Percentage of…
Overactive Bladder
Primary: Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes — 4.4; 4.5; -3.4; -3.2 Incontinence Episodes
Dysmenorrhea
Primary: Patient Response to Treatment for Primary Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 3.8; 3.6; 1.2…
Dysmenorrhea
Primary: Patient Response to Treatment for Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) — 2.4 units on a scale